{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:28:55Z","timestamp":1793424535761,"version":"4.5.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010391","name":"Tokyo Women's Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010391","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["23FC1048"],"award-info":[{"award-number":["23FC1048"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006559","name":"University of Tsukuba","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006559","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007962","name":"Jikei University School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007962","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005946","name":"Hokkaido University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005946","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ekir.2025.03.020","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T04:16:24Z","timestamp":1742184984000},"page":"1864-1873","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Kidney Function Trajectories with Tolvaptan in ADPKD Patients with CKD-G5"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7326-4988","authenticated-orcid":false,"given":"Akinari","family":"Sekine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Hoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Mochizuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Nakatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saori","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Suwabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirayasu","family":"Kai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Seta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiko","family":"Hattanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumi","family":"Hidaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazushige","family":"Hanaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahiro","family":"Kurashige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5173-1263","authenticated-orcid":false,"given":"Kiyotaka","family":"Uchiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Shimazu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruna","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Tsuchiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeo","family":"Horie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiei","family":"Narita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Isaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Muto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2025.03.020_bib1","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(18)32782-X","article-title":"Autosomal dominant polycystic kidney disease","volume":"393","author":"Cornec-Le Gall","year":"2019","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ekir.2025.03.020_bib2","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1681\/ASN.V1171179","article-title":"cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells","volume":"11","author":"Hanaoka","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.03.020_bib3","article-title":"Autosomal dominant polycystic kidney disease","volume":"352","author":"Simms","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.ekir.2025.03.020_bib4","doi-asserted-by":"crossref","first-page":"F1005","DOI":"10.1152\/ajprenal.00243.2011","article-title":"Tolvaptan inhibits ERK-dependent cell proliferation, Cl- secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin","volume":"301","author":"Reif","year":"2011","journal-title":"Am J Physiol Ren Physiol"},{"key":"10.1016\/j.ekir.2025.03.020_bib5","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.03.020_bib6","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.03.020_bib7","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s12882-023-03247-6","article-title":"Effects of tolvaptan discontinuation in patients with autosomal dominant polycystic kidney disease: a post hoc pooled analysis","volume":"24","author":"Lioudis","year":"2023","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ekir.2025.03.020_bib8","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1007\/s10157-021-02059-y","article-title":"Comparison of annual eGFR decline among primary kidney diseases in patients with CKD G3b-5: results from a REACH-J CKD cohort study","volume":"25","author":"Hoshino","year":"2021","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.ekir.2025.03.020_bib9","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1007\/s10157-013-0788-6","article-title":"The effects of tolvaptan on patients with severe chronic kidney disease complicated by congestive heart failure","volume":"17","author":"Otsuka","year":"2013","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.ekir.2025.03.020_bib10","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1007\/s10157-021-02097-6","article-title":"A digest from evidence-based clinical practice guideline for polycystic kidney disease 2020","volume":"25","author":"Nishio","year":"2021","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.ekir.2025.03.020_bib11","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Revised equations for estimated GFR from serum creatinine in Japan","volume":"53","author":"Matsuo","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2025.03.020_bib12","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/ki.2011.119","article-title":"Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease","volume":"80","author":"Irazabal","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.03.020_bib13","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1016\/j.ekir.2021.05.037","article-title":"Tolvaptan in ADPKD patients with very low kidney function","volume":"6","author":"Torres","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2025.03.020_bib14","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1124\/jpet.114.213256","article-title":"Tolvaptan delays the onset of end-stage renal disease in a polycystic kidney disease model by suppressing increases in kidney volume and renal injury","volume":"349","author":"Aihara","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.ekir.2025.03.020_bib15","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s10157-020-02009-0","article-title":"Preservation of kidney function irrelevant of total kidney volume growth rate with tolvaptan treatment in patients with autosomal dominant polycystic kidney disease","volume":"25","author":"Horie","year":"2021","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.ekir.2025.03.020_bib16","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1681\/ASN.2020020190","article-title":"Epithelial vasopressin Type-2 receptors regulate myofibroblasts by a YAP-CCN2-Dependent mechanism in polycystic kidney disease","volume":"31","author":"Dwivedi","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.03.020_bib17","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.ekir.2017.07.004","article-title":"Tolerability of aquaretic-related symptoms following tolvaptan for autosomal dominant polycystic kidney disease: results from TEMPO 3:4","volume":"2","author":"Devuyst","year":"2017","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2025.03.020_bib18","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2147\/DHPS.S142825","article-title":"Long-term safety profile of tolvaptan in autosomal dominant polycystic kidney disease patients: TEMPO Extension Japan Trial","volume":"9","author":"Muto","year":"2017","journal-title":"Drug Healthc Patient Saf"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024925001639?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024925001639?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T18:50:15Z","timestamp":1762627815000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024925001639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2468024925001639"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2025.03.020","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Kidney Function Trajectories with Tolvaptan in ADPKD Patients with CKD-G5","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2025.03.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier, Inc., on behalf of the International Society of Nephrology.","name":"copyright","label":"Copyright"}]}}